| 1 | CUI Z, ZHAO M H. Advances in human antiglomerular basement membrane disease[J]. Nat. Rev. Nephrol., 2011, 7(12): 697-705. | 
																													
																							| 2 | PEDCHENKO V, BONDAR O, FOGO A B, et al.. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis[J]. N. Engl. J. Med., 2010, 363(4): 343-354. | 
																													
																							| 3 | HELLMARK T, SEGELMARK M, UNGER C, et al.. Identification of a clinically relevant immunodominant region of collagen Ⅳ in Goodpasture disease[J]. Kidney Int., 1999, 55(3): 936-944. | 
																													
																							| 4 | HU S Y, JIA X Y, GU Q H, et al.. T cell responses to peptides of Goodpasture autoantigen in patients with anti-glomerular basement membrane disease[J]. Nephrology (Carlton), 2018, 23(4): 345-350. | 
																													
																							| 5 | OOI J D, PETERSEN J, TAN Y H, et al.. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells[J]. Nature, 2017, 545(7653): 243-247. | 
																													
																							| 6 | JIA X Y, CUI Z, YANG R, et al.. Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury[J]. Clin. J. Am. Soc. Nephrol., 2012, 7(6): 926-933. | 
																													
																							| 7 | CAIRNS L S, PHELPS R G, BOWIE L, et al.. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type Ⅳ collagen in Goodpasture's disease[J]. J. Am. Soc. Nephrol., 2003, 14(11): 2801-2812. | 
																													
																							| 8 | WU J, HICKS J, BORILLO J, et al.. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis[J]. J. Clin. Invest., 2002, 109(4): 517-524. | 
																													
																							| 9 | 李耿,刘晓志,王志明,等. 双特异性抗体药物应用进展[J]. 生物技术进展, 2015, 5(06): 420-424. | 
																													
																							| 10 | MCADOO S P, REYNOLDS J, BHANGAL G, et al.. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN[J]. J. Am. Soc. Nephrol., 2014, 25(10): 2291-2302. | 
																													
																							| 11 | IYODA M, SHIBATA T, WADA Y, et al.. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis[J]. Nephrol. Dial. Transplant., 2013, 28(3): 576-584. | 
																													
																							| 12 | REYNOLDS J, PRESTON G A, PRESSLER B M, et al.. Autoimmunity to the alpha 3 chain of type Ⅳ collagen in glomerulonephritis is triggered by 'autoantigen complementarity'[J]. J. Autoimmun., 2015, 59: 8-18. | 
																													
																							| 13 | REYNOLDS J, MOSS J, DUDA M A, et al.. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease[J]. J. Pathol., 2003, 200(1): 118-129. | 
																													
																							| 14 | CANNEY M, O'HARA P V, MCEVOY C M, et al.. Spatial and temporal clustering of anti-glomerular basement membrane disease[J]. Clin. J. Am. Soc. Nephrol., 2016, 11(8): 1392-1399. | 
																													
																							| 15 | MCADOO S P, PUSEY C D. Anti-glomerular basement membrane disease[J]. Clin. J. Am. Soc. Nephrol., 2017, 12(7): 1162-1172. | 
																													
																							| 16 | REYNOLDS J, COOK P R, BEHMOARAS J, et al.. Genetic susceptibility to experimental autoimmune glomerulonephritis in the Wistar Kyoto rat[J]. Am. J. Pathol., 2012, 180(5): 1843-1851. | 
																													
																							| 17 | SADO Y, BOUTAUD A, KAGAWA M, et al.. Induction of anti-GBM nephritis in rats by recombinant alpha 3(Ⅳ)NC1 and alpha 4(Ⅳ)NC1 of type Ⅳ collagen[J]. Kidney Int., 1998, 53(3): 664-671. | 
																													
																							| 18 | ABBATE M, KALLURI R, CORNA D, et al.. Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type Ⅳ collagen[J]. Kidney Int., 1998, 54(5): 1550-1561. | 
																													
																							| 19 | ROBERTSON J, WU J, ARENDS J, et al.. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis[J]. Kidney Int., 2005, 68(3): 1061-1070. | 
																													
																							| 20 | WU J, BORILLO J, GLASS W F, et al.. T-cell epitope of alpha3 chain of type Ⅳ collagen induces severe glomerulonephritis[J]. Kidney Int., 2003, 64(4): 1292-1301. | 
																													
																							| 21 | WU J, HICKS J, OU C, et al.. Glomerulonephritis induced by recombinant collagen Ⅳ alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: a potential T cell-mediated mechanism[J]. J. Immunol., 2001, 167(4): 2388-2395. | 
																													
																							| 22 | YU X, PETERSEN F. A methodological review of induced animal models of autoimmune diseases[J]. Autoimmun. Rev., 2018, 17(5): 473-479. | 
																													
																							| 23 | HU S Y, GU Q H, WANG J, et al.. The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif[J]. J. Cell Mol. Med., 2017, 21(9): 2117-2128. | 
																													
																							| 24 | REYNOLDS J, NORGAN V A, BHAMBRA U, et al.. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis[J]. J. Am. Soc. Nephrol., 2002, 13(2): 359-369. |